

Supplementary Materials

Nitric oxide/L-arginine-related pathway metabolites are altered in patients after myocardial infarction and predict adverse outcomes




Figure S1. Endogenous NO/L-Arginine-related pathway metabolites plasma concentrations in patients with acute myocardial infarction (AMI), compared to healthy controls. A: Arginine (ARG), B: Ornithine (ORN).




Figure S2. Concentrations of endogenous NO/L-Arginine-related pathway metabolites in patients after acute myocardial infarction (AMI) who developed major adverse cardiovascular events (MACE), compared to those who did not during the median follow-up of 3.5 years. A: asymmetric dimethylarginine (ADMA), B: Arginine (ARG), C: Ornithine (ORN), D: Citrulline (CIT).